HomeAIMOVIG

  • Novartis wins Aimovig approval for launch in the EU markets

    • August 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Unprecedented demand for Aimovig reflects strong unmet need in Migraine, says Novartis CEO

    • July 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • ICER report gives thumbs up to Aimovig for Chronic Migraine patients

    • July 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Novartis presents new Aimovig data to reinforce its efficacy, safety and tolerability

    • June 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Aimovig for Migraine receives positive CHMP opinion by EMA, might get approved soon in EU

    • June 2, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA approves Aimovig, first aCGRP drug for preventive treatment of Migraine

    • May 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Aimovig halves Migraine days in difficult to treat patients, study to be presented an AAN finds

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Migraine CGRP drugs assessed for Clinical effectiveness & Economic impacts by recent ICER report

    • April 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more